The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

RPRX FINANCIAL STATEMENTS

Royalty Pharma Plc — balance sheet, income statement and cash flow trends

RPRXRoyalty Pharma Plc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
01 B2 B2020202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue2.5 B $Gross Profit2.3 B $ · 89%Operating Income1.6 B $ · 62%Pre-tax Income1.3 B $ · 53%Net Income to Owners815.3 M $ · 32%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue2.5 B $+10.0%
Gross Profit2.3 B $-1.7%
Operating Income1.6 B $-14.1%
EBITDA1.7 B $-11.2%
Net Income to Owners815.3 M $-20.1%

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
010 B20 B2020202120222023202420252026

Capital Structure

Q2 2026
Total Assets19.8 B
  • Equity9.8 B $49%
  • Current Liabilities630.9 M $3%
  • Long-term Liabilities9.4 B $47%

Key Figures

YoY change
Total Assets19.8 B $+8.2%
Total Liabilities10 B $+13.8%
Total Equity9.8 B $+54.2%
Cash & ST Investments812 M $-45.4%
Total Debt9 B $+12.0%
Net Debt-812 M $-111.0%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
01 B2 B3 B2020202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
01 B2 B3 B3 B $Operating-2.6 B $Investing-282.5 M $Financing179.5 M $Net Change

Key Figures

YoY change
Operating Cash Flow3 B $+25.4%
Capital Expenditures1.1 M $-99.9%
Free Cash Flow3 B $+25.4%
Dividends Paid-399.1 M $-310.3%

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on RPRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 3, 26. This content is for informational purposes only and is not investment advice.